BR112021003997A2 - composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma - Google Patents

composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma Download PDF

Info

Publication number
BR112021003997A2
BR112021003997A2 BR112021003997-0A BR112021003997A BR112021003997A2 BR 112021003997 A2 BR112021003997 A2 BR 112021003997A2 BR 112021003997 A BR112021003997 A BR 112021003997A BR 112021003997 A2 BR112021003997 A2 BR 112021003997A2
Authority
BR
Brazil
Prior art keywords
cyclodextrin
formula
day
composition
dithiol
Prior art date
Application number
BR112021003997-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicolas Pineau
El Mustapha Belgsir
Frédéric TURPIN
Anne-Gaëlle FOURNIAL
Aswin DEREYMAKER
Natascha AUDOORE
Ine De Cock
Original Assignee
OP2 Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OP2 Drugs filed Critical OP2 Drugs
Publication of BR112021003997A2 publication Critical patent/BR112021003997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112021003997-0A 2018-09-06 2019-09-06 composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma BR112021003997A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862727691P 2018-09-06 2018-09-06
EP18306172 2018-09-06
EP18306172.0 2018-09-06
US62/727,691 2018-09-06
PCT/EP2019/073873 WO2020049166A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Publications (1)

Publication Number Publication Date
BR112021003997A2 true BR112021003997A2 (pt) 2021-05-25

Family

ID=67841092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021003997-0A BR112021003997A2 (pt) 2018-09-06 2019-09-06 composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma

Country Status (11)

Country Link
US (1) US12295969B2 (https=)
EP (1) EP3846856A1 (https=)
JP (1) JP7362725B2 (https=)
KR (1) KR20210054540A (https=)
CN (1) CN113038969A (https=)
AU (2) AU2019336943A1 (https=)
BR (1) BR112021003997A2 (https=)
CA (1) CA3111886A1 (https=)
IL (1) IL281161B2 (https=)
MX (1) MX2021002611A (https=)
WO (1) WO2020049166A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123038A1 (en) * 2020-12-10 2022-06-16 OP2 Drugs Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757B (zh) * 2022-11-24 2024-03-29 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2222133C (en) 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1771938A (zh) 2004-11-09 2006-05-17 胡才忠 茴三硫脂质体及其制备方法
JP6876047B2 (ja) * 2015-09-08 2021-05-26 オーピーツー ドラッグス ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物
BR112018004518A2 (pt) * 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
AU2018232799B2 (en) * 2017-03-07 2021-11-25 Centre Hospitalier Universitaire De Bordeaux Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Also Published As

Publication number Publication date
AU2019336943A1 (en) 2021-03-18
JP2021536472A (ja) 2021-12-27
IL281161B2 (en) 2024-01-01
KR20210054540A (ko) 2021-05-13
IL281161B1 (en) 2023-09-01
US20210308173A1 (en) 2021-10-07
MX2021002611A (es) 2021-07-21
CA3111886A1 (en) 2020-03-12
IL281161A (en) 2021-04-29
CN113038969A (zh) 2021-06-25
AU2025204144A1 (en) 2025-06-26
EP3846856A1 (en) 2021-07-14
US12295969B2 (en) 2025-05-13
JP7362725B2 (ja) 2023-10-17
WO2020049166A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
BR112021003997A2 (pt) composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma
US20110224268A1 (en) Compositions and methods of using R(+) pramipexole
JP2018534343A (ja) ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物
BRPI0618661A2 (pt) composições de inibidores de lipoxigenase
BR112019018495A2 (pt) derivados de desmetilanetola tritiona para o tratamento de doenças relacionadas com a produção mitocondrial de espécies de oxigênio reativo (ero)
ES2369089T3 (es) Gotas oftálmicas acuosas con migración intraocular acelerada.
WO2010056145A1 (ru) Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
ES2618374T3 (es) Composiciones y métodos para mejorar la absorción de glucosa
PT842165E (pt) Derivados de acido tiazolidina-4-carboxilico como agentes citoprotectores
KR100342367B1 (ko) 녹내장치료제및안압강하제
BRPI0618653A2 (pt) composições compreendendo inibidores da lipoxigenase e ciclodextrina
BR112020011160A2 (pt) composição tópica oftálmica para o tratamento de doenças do segmento posterior do olho
CA3005527C (fr) Mirabegron pour le traitement de maladies retiniennes
US20210346332A1 (en) Compositions and methods for treating and preventing leber's hereditary optic neuropathy
WO2020067055A1 (ja) 抗神経変性疾患剤
WO2016068278A1 (ja) 水晶体硬化抑制剤
KR20160113720A (ko) 황 함유 모이어티를 포함하는 당 유도체 및 이의 제조 방법 및 mps iiic의 치료를 위한 이의 사용 방법
EP2586776A1 (en) Soft cationic mitochondrial uncouplers
EP3045169A1 (en) Aqueous solution formulation, and manufacturing method for same
RU2775597C2 (ru) Ингибитор продукции реактивных форм кислорода для лечения заболеваний, связанных со свободными радикалами кислорода
JPH03157385A (ja) 細胞防護剤
RU2527519C2 (ru) Мягкие катионные митохондриальные разобщители

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA EXIGENCIA TECNICA (DESPACHO 6.23) NOTIFICADO NA RPI NO 2790 DE 25/06/2024, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES, UMA VEZ QUE A IMAGEM DO REFERIDO PARECER NAO FOI DISPONIBILIZADA AO PUBLICO.